Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of ID110521156 in Healthy Subjects
NCT06063291Phase 1Completed
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ID110521156 in type 2 diabetes mellitus (T2DM) and obesity (4 cohorts), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoints: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 9 days and Percentage of subjects with clinically significant change from baseline in vital signs, ECG, safety laboratory test results up to 9 days. Started Nov 2023; status: completed.
02
Drugs
ID110521156
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06063291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063291.